论文部分内容阅读
目的:观察芪参胶囊联合曲美他嗪治疗冠心病稳定型心绞痛的临床疗效。方法:120例冠心病稳定型心绞痛患者随机分为观察组和对照组,各60例。对照组应用复方丹参滴丸联合曲美他嗪治疗;观察组应用芪参胶囊联合曲美他嗪治疗。2组连续治疗6周。结果:总有效率观察组91.67%,对照组73.33%,2组比较,差异有统计学意义(P<0.05)。治疗后2组ST段降低导联、ST段下降电压总和较治疗前均有不同程度的变化,与本组治疗前比较,差异有统计学意义(P<0.05)。2组治疗后ST段下降电压总和、ST段降低导联改善大于对照组,与对照组比较,差异有统计学意义(P<0.05)。治疗后2组心绞痛持续时间和心绞痛发作频率较治疗前有改善,与本组治疗前比较,差异有统计学意义(P<0.05),且观察组心绞痛持续时间和心绞痛发作频率与对照组比较,差异有统计学意义(P<0.05)。结论:芪参胶囊联合曲美他嗪治疗冠心病稳定型心绞痛效果显著,并缩短心绞痛持续时间和发作频率。
Objective: To observe the clinical efficacy of Qishen capsule combined with trimetazidine in treatment of stable angina pectoris of coronary heart disease. Methods: 120 patients with coronary heart disease with stable angina were randomly divided into observation group and control group, with 60 cases each. The control group was treated with compound Danshen dripping pills and trimetazidine. The observation group was treated with Qishen capsule combined with trimetazidine. Two groups of continuous treatment for 6 weeks. Results: The total effective rate was 91.67% in the observation group and 73.33% in the control group. There was significant difference between the two groups (P <0.05). After treatment, the ST segment descending leads and the ST segment descending voltage summation had different degrees of change before treatment, which were significantly different from those before treatment (P <0.05). After treatment, the total ST-segment depression voltage and the ST-segment reduction lead improved more than those of the control group. The difference was statistically significant (P <0.05). The duration of angina pectoris and the frequency of angina pectoris in both groups after treatment were improved compared with that before treatment, and the difference was statistically significant (P <0.05) before treatment, and the duration of angina pectoris and angina pectoris frequency in the observation group compared with the control group, The difference was statistically significant (P <0.05). Conclusion: Qishen capsule combined with trimetazidine treatment of coronary heart disease with stable angina significantly, and shorten the duration and frequency of angina pectoris.